Yuki Noguchi

Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C. She started covering consumer health in the midst of the pandemic, reporting on mental health, vaccination, telehealth, and racial inequities in healthcare. Noguchi joined NPR as a business correspondent in 2008, just before the financial crisis and Great Recession. She has covered a wide range of issues from the impact of opioids on workers and their families to the coverage of medical debt in partnership with Kaiser Health News. Yuki grew up in St. Louis, likes to cook, has a degree in history from Yale and is raising two boys and two rescue dogs outside Washington DC.

Biography:  https://www.npr.org/people/96022165/yuki-noguchi

48%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a poor reputation for journalistic standards and is not considered a reliable news source.

Bias

10%

Examples:

  • Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C.

Conflicts of Interest

90%

Examples:

  • Noguchi grew up in St. Louis, likes to cook, has a degree in history from Yale and is raising two boys and two rescue dogs outside Washington DC.

Contradictions

20%

Examples:

  • GLP-1 drugs rely on Semaglutide as an active ingredient which reduces users' appetites.
  • Users tend to shed between 15% to 20% of their weight on these injectable meds.

Deceptions

30%

Examples:

  • Many of these people that we're hearing that from, don't actually qualify for the strict criteria of the medicine.
  • The new obesity treatments act on the various hormonal and metabolic drivers of obesity. It would make sense that once we stop the therapy for those biological problems, that we would have relapse.

Recent Articles

New Study Shows Over One-Third of GLP-1 Drug Users Discontinue Medication Within a Year Due to Costs and Side Effects

New Study Shows Over One-Third of GLP-1 Drug Users Discontinue Medication Within a Year Due to Costs and Side Effects

Broke On: Friday, 24 May 2024 A recent study published in JAMA Network Open found that over one-third of patients discontinued use of GLP-1 weight-loss drugs like Wegovy and Ozempic within a year due to costs, gastrointestinal side effects, and availability issues. Obese individuals without type 2 diabetes were more likely to quit than those with diabetes. Despite potential health benefits, high costs and side effects pose challenges for long-term use.